Zacks Reaffirms “Neutral” Rating for Pfizer (PFE)
Pfizer (NYSE:PFE)‘s stock had its “neutral” rating reaffirmed by Zacks in a research note issued on Friday. They currently have a $30.00 price objective on the stock. Zacks‘s price target suggests a potential upside of 4.09% from the company’s current price.
Zacks’ analyst wrote, “Pfizer’s second quarter 2014 earnings of $0.58 per share were a couple of cents above the Zacks Consensus Estimate and 4% above the year-ago earnings. Revenues, which declined 2% to $12.8 billion, were above the Zacks Consensus Estimate of $12.4 billion. Revenues were impacted by the loss of exclusivity of certain products including Detrol LA (in the U.S.), the expiry of the Spiriva collaboration in some countries and the Enbrel agreement. Although Pfizer maintained its guidance for 2014, the company cut its revenue outlook. We believe revenues will remain under pressure going forward. However, cost-cutting efforts and share buybacks should help Pfizer achieve its earnings guidance. We remain Neutral on the stock.”
Pfizer (NYSE:PFE) traded up 0.49% during mid-day trading on Friday, hitting $28.96. 10,272,465 shares of the company’s stock traded hands. Pfizer has a one year low of $27.76 and a one year high of $32.96. The stock has a 50-day moving average of $29.48 and a 200-day moving average of $30.40. The company has a market cap of $183.6 billion and a P/E ratio of 18.10.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.58 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.57 by $0.01. The company had revenue of $12.80 billion for the quarter, compared to the consensus estimate of $12.49 billion. During the same quarter last year, the company posted $0.56 earnings per share. Pfizer’s revenue was down 1.5% compared to the same quarter last year. Analysts expect that Pfizer will post $2.25 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse cut their price target on shares of Pfizer from $35.00 to $34.00 in a research note on Thursday, August 14th. Separately, analysts at BMO Capital Markets downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating in a research note on Monday, July 28th. They now have a $31.00 price target on the stock, down previously from $34.00. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pfizer in a research note on Monday, July 14th. They now have a $38.00 price target on the stock, up previously from $36.00. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $33.51.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.